{"id":"W2990602488","doi":"10.1200/jco.2012.30.15_suppl.4099","title":"A phase II trial of temsirolimus (TEM) and bevacizumab (BEV) in patients with advanced hepatocellular carcinoma (HCC).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Neutropenia; Temsirolimus; Internal medicine; Hepatocellular carcinoma; Bevacizumab; Adverse effect; Gastroenterology; Phases of clinical research; Clinical endpoint; Toxicity; Progression-free survival; Response Evaluation Criteria in Solid Tumors; Oncology; Surgery; Chemotherapy; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001922734,0.001228675,0.001507519,0.0004415919,0.0003270323,0.0007639821,0.000559057,0.0009988867,0.005032839],"category_scores_gemma":[0.0008512257,0.0006358357,0.0007544165,0.0004350828,0.0007693538,0.0007707241,0.0004544868,0.00222512,0.0009878461],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007845829,"about_ca_system_score_gemma":0.001508954,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006180766,"about_ca_topic_score_gemma":0.001775086,"domain_scores_codex":[0.999571,0.000246155,0.00002353882,0.0000558606,0.00003057107,0.00007274058],"domain_scores_gemma":[0.9993992,0.0001033431,0.00008976874,0.00003032495,0.00002115186,0.0003562623],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9019108,0.02685548,0.003990259,0.000464303,0.0004991211,0.0001997918,0.0001496573,0.001315112,0.01298624,0.0003308201,0.003323676,0.04797471],"study_design_scores_gemma":[0.822713,0.1691519,0.004128001,0.00001896259,0.0001423227,0.0001495042,0.00002813358,0.0008424928,0.0008027463,0.0001556834,0.00185523,0.00001198721],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9882715,0.002307806,0.0005302849,0.0009352131,0.0002268181,0.003542285,0.001019214,0.00009479346,0.003072162],"genre_scores_gemma":[0.9837252,0.001448318,0.002034625,0.001214718,0.0002643965,0.004358627,0.00285764,0.00002447312,0.004071985],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005032839,"threshold_uncertainty_score":0.01683652,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1261380461796786,"score_gpt":0.3928745238200259,"score_spread":0.2667364776403473,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}